Furiex Pharmaceuticals Inc (FURX)

[surf1944]

4:11PM Furiex Pharmaceuticals announced successful results from its Phase II proof-of-concept clinical trial of MuDelta; MuDelta met its primary objectives of establishing tolerability, safety and efficacy in a 12-week randomized, double-blind, placebo-controlled study (FURX) 13.74 : Co announces successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome. IBS-D is a common functional bowel disorder that causes chronic diarrhea and abdominal pain. MuDelta met its primary objectives of establishing tolerability, safety and efficacy in a 12-week randomized, double-blind, placebo-controlled study. The study achieved statistically and clinically significant results for its primary as well as a number of key secondary endpoints. MuDelta also demonstrated durable efficacy through the 12-week treatment period.